1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

por Joshi, K., Muhith, A., Milner-Watts, C., Obeid, M., Khakoo, S., Bhosle, J., Minchom, A.R., O'Brien, M.
Publicado 2020

1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience

por Cui, W., Yousaf, N., Bhosle, J., Minchom, A.R., Ahmed, M., McDonald, F., Locke, I., Lee, R., O'Brien, M., Popat, S.
Publicado 2020

180P Incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19

por Cui, W., Milner-Watts, C., Saith, S., Bhosle, J., Minchom, A.R., Davidson, M., Page, S., Locke, I., Yousaf, N., Popat, S., O'Brien, M.E.R.
Publicado 2021

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B(12) and folic acid supplementation in the treatment of lung cancer with plasma homocysteine bl...

por Minchom, A R, Saksornchai, K, Bhosle, J, Gunapala, R, Puglisi, M, Lu, S K, Nimako, K, Coward, J, Yu, K C, Bordi, P, Popat, S, O'Brien, M E R
Publicado 2014